Henry Schein FY2025 EPS Forecast Lifted by Zacks Research

Key Points

• Zacks Research has raised its earnings per share (EPS) estimate for Henry Schein for FY2025 to $4.81, up from a previous estimate of $4.80.
• Henry Schein's stock is being rated mostly as a "Hold" by analysts, with an average target price of $76.67.
• As of the latest report, shares of Henry Schein are down 0.6% and have a market cap of $8.29 billion.

Henry Schein, Inc. (NASDAQ:HSIC - Free Report) - Equities researchers at Zacks Research raised their FY2025 EPS estimates for shares of Henry Schein in a research note issued to investors on Monday, September 15th. Zacks Research analyst Team now forecasts that the company will earn $4.81 per share for the year, up from their prior forecast of $4.80. The consensus estimate for Henry Schein's current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Henry Schein's Q4 2026 earnings at $1.38 EPS and Q2 2027 earnings at $1.39 EPS.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.09). The firm had revenue of $3.24 billion during the quarter, compared to analysts' expectations of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The firm's revenue was up 3.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.23 EPS. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS.

HSIC has been the topic of a number of other research reports. Baird R W lowered shares of Henry Schein from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 14th. Stifel Nicolaus restated a "hold" rating and issued a $75.00 price target (down from $80.00) on shares of Henry Schein in a research note on Friday, July 25th. Evercore ISI raised shares of Henry Schein from an "in-line" rating to an "outperform" rating and set a $83.00 target price for the company in a report on Tuesday, August 26th. Wall Street Zen downgraded shares of Henry Schein from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Finally, Leerink Partners set a $75.00 price objective on shares of Henry Schein in a research report on Monday, July 14th. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat, Henry Schein currently has an average rating of "Hold" and a consensus price target of $76.67.

Henry Schein Price Performance

HSIC traded down $0.69 during midday trading on Wednesday, hitting $67.86. The company had a trading volume of 5,625,720 shares, compared to its average volume of 1,392,004. Henry Schein has a twelve month low of $60.56 and a twelve month high of $82.49. The firm's 50-day simple moving average is $68.75 and its 200-day simple moving average is $69.35. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41. The company has a market capitalization of $8.23 billion, a PE ratio of 21.89, a P/E/G ratio of 2.24 and a beta of 0.86.

Institutional Trading of Henry Schein

Hedge funds have recently bought and sold shares of the company. CYBER HORNET ETFs LLC bought a new stake in Henry Schein in the second quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein in the second quarter worth $27,000. Investment Management Corp VA ADV bought a new position in shares of Henry Schein during the fourth quarter valued at $32,000. Rakuten Securities Inc. bought a new position in shares of Henry Schein during the first quarter valued at $34,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in Henry Schein in the second quarter valued at about $43,000. Institutional investors own 96.62% of the company's stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.